Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Real-world anti-VEGF treatment experience study of the management of neovascular age-related macular degeneration in the UK (RATE study): Early insights

Author: Robin Hamilton (United Kingdom)

Co-authors: Konstantinos Balaskas, Sesan Oyetunde, Kuldip Grewal, Fiona Glen, Luke Saunders, Louise Downey

Purpose

Age-related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom (UK), with the number of new cases and associated costs to the UK economy continuing to rise alongside an increase in life expectancy and an ageing population. In the UK, the standard therapy for treatment of neovascular AMD (nAMD) is intravitreal injection of anti–vascular endothelial growth factor (anti-VEGF) therapy. Prompt intervention with anti-VEGF treatment and continued maintenance of therapy following early diagnosis of nAMD is paramount to providing disease control and preserving the vision of patients, with treatment delays likely to lead to irreversible visual loss and subsequent higher social support costs. There has, however, been limited research investigating anti-VEGF treatment patterns and associated clinical outcomes within real-world clinical practice in the UK. The objective of this retrospective non-interventional study was to describe the current management landscape for patients with nAMD treated with anti-VEGF therapy in the UK and associated clinical outcomes during the first 24 months after initiating treatment.

Setting/Venue

The RATE study for nAMD involved the collection of pseudonymised patient and service-level data about current treatment practices and outcomes for patients newly initiated on licensed anti-VEGF therapy at eighteen hospitals within the UK National Health Service. Participating centres were from a diverse setting of teaching and district general hospitals spread geographically across England and Wales. Data were collected using a mixed-methodology approach that involved the retrospective review of patient medical records, additional independent interpretation of medical imaging results and a service mapping survey with healthcare professionals: early results from the medical record review are presented here.

Methods

Patients were sequentially included if they had been initiated on a licensed anti-VEGF therapy (aflibercept or ranibizumab) for nAMD and received ≥1 intravitreal injection between 01/01/2017 and 31/12/2017. (The date of the first injection is the ‘index date’; the eye that received first injection is the ‘index eye’). Patients were required to be aged ≥50 years at index, have a first diagnosis of nAMD on or within 60 days prior to the index date, and be anti-VEGF treatment naive in both eyes. Data were analysed using descriptive statistics (analyses included data on the index eye only). Key treatment and clinical outcomes during the 12 months post-index are presented here. For the purpose of this analysis, disease control was defined as the absence of retinal fluid (no intra-retinal [IRF] and no sub-retinal fluid [SRF]), as documented in medical records by the treating physician in relation to the most recent optical coherence tomography (OCT) result at Month 12 (±2 months). OCT scans were also independently assessed by a central reading centre and these data will form the basis of further analyses. Change in visual acuity (VA) from baseline (the closest pre-index measurement) was assessed in Early Treatment Diabetic Retinopathy Study (ETDRS) letters.

Results

Of the 331 patients included in this analysis, the median (interquartile range [IQR]) age at index was 79 (74–84) years and 200 (60%) patients were female. The median (IQR) duration from nAMD diagnosis until first anti-VEGF injection was 2 (0–11.5) days. All patients received a NICE-approved anti-VEGF therapy for nAMD: 194 (59%) patients received aflibercept and 137 (41%) received ranibizumab. 313 (95%) patients received at least three anti-VEGF injections within 90 days after the index date, with patients receiving a mean (standard deviation [SD]) of 7.3 (2.0) injections during the 12 months post-index. Of 256 patients with available information on IRF and SRF status and at least 12 months follow-up, 117 (46%) were documented to have achieved disease control in the index eye at Month 12. The median (IQR) VA at baseline (n=304) was 55.0 (45.0 - 65.0) ETDRS letters. There was a median (IQR) increase in VA from baseline of 6.5 (0.0–15.0) letters at Month 3 (n=300), 7.0 (0.0–16.0) letters at Month 6 (n=286), 9.0 (0.2–16.0) letters at Month 9 (n=270) and 7.0 (0.0–18.0) letters at Month 12 (n=253 [all p<0.001]).

Conlusions

Early results from the RATE study indicated that at month 12, disease control was achieved in approximately half of patients initiated on a licensed anti-VEGF therapy, with VA improving by a median of 7 letters. Within UK clinical practice, there was prompt access to anti-VEGF treatment (within 2 days on average of diagnosis) and 95% of patients received ≥3 anti-VEGF injections within 90 days, in alignment with recommendations that a loading phase of three injections at monthly intervals is completed for patients newly initiated on treatment. Patients received a mean of 7.3 injections in total within the first year, suggesting that centres are opting to extend the intervals between injections after completion of the loading phase (the service mapping analysis completed as part of this study will further clarify treatment protocols used within these centres). It will also be important to understand the extent to which service capacity issues, treatment protocols and VA outcomes influence treatment interval decisions. Further planned analyses will consider wider aspects of the management and visual outcomes of patients with nAMD during the first 24 months of treatment, including anti-VEGF regimens and treatment patterns and the wider structure of UK retinal services.

Financial Disclosure

Robin Hamilton: Consultant for Allergan, Bayer Healthcare, Novartis Pharmaceuticals, and Roche; Receives grants from Bayer Healthcare, Novartis Pharmaceuticals and Roche; Receives lecture fees from Allergan, Roche, Bayer Healthcare, and Novartis Pharmaceuticals. Sesan Oyetunde: Employee of Novartis Pharmaceuticals UK. Kuldip Grewal: Employee of Novartis Pharmaceuticals UK. Fiona Glen: Employee of Open Health, who have received funding from Novartis Pharmaceuticals UK. Luke Saunders: Employee of Open Health, who have received funding from Novartis Pharmaceuticals UK. Konstantinos Balaskas: Consultant for Novartis and Roche; Research grants from Bayer Healthcare, Novartis Pharmaceuticals, Roche, Apellis; Speaker fees from Roche, Bayer, Novartis, Alimera, Heidelberg engineering. Louise Downey: Consultant for Alimera, Allergan, Bayer Healthcare, Novartis Pharmaceuticals, and Roche; Receives grants from Allergan, Bayer Healthcare and Novartis Pharmaceuticals; Receives lecture fees from Alimera, Allergan, Bausch and Lomb, Bayer Healthcare, Novartis Pharmaceuticals and Roche.

Comments

-
PrevPrevious
NextNext
Euretina Logo, Links to homepage.

European Society of Retina Specialists c/o Congrex Switzerland
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

General Enquires: [email protected]

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2026 All rights reserved

  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login